Anticoagulant Therapy

November, 2022 Quick Question

Please visit and respond to our November 2022 Quick Question, submitted by Dave McGlasson. The question asks, "If you use the PT when no warfarin is being measured, how do you

Dr. Karen Moser Coag Conversation: The DOACs Part 2

Our Coag Conversation series sponsored by BioMedica Diagnostics continues with Dr. Karen Moser

Anticoagulant Therapy

Northeast Laboratory Conference 10/18–10/19 2022

At the 2022 Northeast Laboratory Conference, October 18 and 19, I [Geo] presented "Antithrombotic Therapy, Whatever Happened to Warfarin?"

Dr. Karen Moser’s Coag Conversation: The DOACs

George Fritsma and guest speaker Karen Moser, MD, Medical Director of the Hemostasis and Thrombosis Laboratory at ARUP Laboratories and Associate

Anticoagulant Therapy

Sulodexide Improves Long Covid

Here is a breakthrough study from Tunisia indicating the efficacy of sulodexide [Aterina], the oral “fast-moving heparin”-dermatan sulfate formulation, in managing the endothelial dysfunction of and reducing the symptoms associated with Long Covid. Sulodexide is not FDA-approved for Long Covid therapy. Charfeddine S, Ibnhadjamor H, Jdidi J, et al. Sulodexide significantly improves endothelial dysfunction and […]

Anticoagulant Therapy

ISTH Covid Antithrombotics Guidelines

On Wednesday, 8-3-22, the ISTH published comprehensive guidelines recommending for or against antithrombotic agents for Covid at defined levels of severity. Below are the task force guidelines and an editorial describing the research considerations behind guideline development. Schulman S, Sholzberg M, Spyropoulos AC, et al. ISTH guidelines for antithrombotic treatment in COVID-19. JTH 2022, DOI: […]

Anticoagulant Therapy

Heparin Curve to Measure DOACs?

Does your facility measure rivaroxaban or apixaban using a chromogenic substrate anti-Xa assay based on unfractionated heparin [UFH] calibrators or UFH-low molecular weight heparin [UFH-LWMH] ‘hybrid” calibrators, or do you require rivaroxaban and apixaban calibrators? I [Geo] received a 6-22-22 response from international hemostasis expert Robert Gosselin, who cited several references. Many of us use […]

Anticoagulant Therapy

April 2022 QQ: Measuring Heparin Summary

Hello, our April 2022 Quick Question asks, “How do you measure unfractionated heparin [UFH]?” Our 37 respondents answered… Chromogenic anti-Xa using a hybrid curve: 38% [14] Chromogenic anti-Xa using the UFH curve: 14% [5] Anti-Xa and PTT: 22% [8] PTT: 26% [9] The majority of respondents are using the chromogenic anti-Xa heparin assay, and most […]

Anticoagulant Therapy

April 2022 QQ: Measuring Heparin

Our April 2022 Quick Question reprises our May 16, 2012 post, “Who Uses the Hybrid Curve?” but adds a twist based on May JE, Siniard RD, Taylor LJ, Marques MB, Gangaraju R. From activated partial thromboplastin time to anti-factor Xa and back again; the evolution of monitoring unfractionated heparin. Am J Clin Pathol 2022;157:321–7 HTTPS://DOI.ORG/10.1093/AJCP/AQAB135. […]

Anticoagulant Therapy

March 2022 Quick Question Summary

The stem of our March 2022 Quick Question was, “How do you measure the anti-Xa DOACs rivaroxaban or apixaban?” The question drew 33 responses and here are the answer selections: We don’t measure the anti-Xa DOACs: 24% [8] Chromogenic anti-Xa using DOAC-specific calibrators and controls: 64% [21] Chromogenic anti-Xa using the unfractionated heparin curve: 3% […]

Anticoagulant Therapy

Load more

George Fritsma is a medical laboratory scientist, educator, and author. George is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question